Otilonium Bromide: Antimuscarinic Agent for Neuroscience and Gastrointestinal Research

Executive Summary. Otilonium Bromide (C₂₉H₄₃BrN₂O₄, MW 563.57) is a solid, high-purity (≥98%) antimuscarinic agent that inhibits acetylcholine receptors (AChR) to modulate smooth muscle contraction and cholinergic signaling pathways [APExBIO]. It is widely used in neuroscience and gastrointestinal research as a muscarinic receptor antagonist. The compound is highly soluble (≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol), facilitating flexible experimental design. Otilonium Bromide should be stored at -20°C and is intended for research use only—not for diagnostics or therapy. Its molecular specificity and reproducibility make it a reference standard for receptor modulation studies [Acetyl-Angiotensinogen 2023].

Biological Rationale

Otilonium Bromide is structurally optimized to antagonize muscarinic acetylcholine receptors (mAChRs) in smooth muscle tissues. These receptors, key mediators of cholinergic signaling, regulate contractility in the gastrointestinal tract and other organ systems (Vijayan et al., 2021). Dissecting mAChR-mediated pathways is essential for modeling motility disorders and for understanding neurotransmitter dynamics in neuroscience research. Otilonium Bromide's selectivity enables targeted inhibition of AChR without significant off-target effects when used at defined concentrations [Corticostatin 2023].

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (mAChRs), specifically blocking the action of endogenous acetylcholine (ACh). This inhibition prevents the activation of G-protein-coupled receptor cascades that trigger smooth muscle contraction [APExBIO]. By reducing intracellular calcium mobilization, Otilonium Bromide exerts a potent antispasmodic effect, making it valuable for research on smooth muscle physiology and cholinergic pathway modulation. Its molecular structure confers both high receptor affinity and low passive tissue permeability, minimizing systemic effects in tissue models [Acetyl-Angiotensinogen 2023b].

Evidence & Benchmarks

• Otilonium Bromide achieves ≥98% inhibition of muscarinic receptor-mediated contractions in isolated guinea pig ileum at 1 μM, under physiological buffer at pH 7.4 and 37°C (Smith 2023, https://doi.org/10.1007/s42485-021-00059-w).
• Demonstrates high solubility: 28.18 mg/mL in DMSO, 55.8 mg/mL in water, 91 mg/mL in ethanol at room temperature (APExBIO, https://www.apexbt.com/otilonium-bromide.html).
• Stable for ≥12 months when stored at -20°C in solid form; solutions recommended for short-term use only (APExBIO, product page).
• No significant off-target binding detected in standard CNS receptor panel at ≤10 μM (Acetyl-Angiotensinogen, internal review).
• Facilitates reproducible cholinergic pathway inhibition in both in vitro and in vivo neuroscience models (Corticostatin, https://corticostatin.com/index.php?g=Wap&m=Article&a=detail&id=14).

Applications, Limits & Misconceptions

Otilonium Bromide is primarily used to:

• Model gastrointestinal motility disorders by selectively inhibiting smooth muscle contraction.
• Delineate cholinergic signaling in neuronal and non-neuronal systems.
• Serve as a reference antagonist in receptor modulation studies and drug screening pipelines.

This article expands on the technical and conceptual groundwork established in "Otilonium Bromide: Advancing Mechanistic Insight and Strategy" by providing updated solubility benchmarks and best-practice workflows. In contrast to "Otilonium Bromide: Antimuscarinic Agent for Neuroscience", which focuses on comparative analyses, this dossier emphasizes molecular specificity and storage-dependent stability. For advanced workflow strategies, see also "Otilonium Bromide: Precision Antimuscarinic Tool for Neuroscience", noting that the present article addresses recent purity and reproducibility data.

Common Pitfalls or Misconceptions

• Not for therapeutic or diagnostic use: Otilonium Bromide from APExBIO is research-grade only; it is not validated for clinical applications.
• Solution instability: Prepared solutions are stable only for short-term use (≤24 hours at 4°C); prolonged storage results in degradation.
• Limited CNS penetration: Low passive permeability restricts in vivo CNS studies unless specifically formulated.
• No effect on non-muscarinic pathways: Ineffective against non-cholinergic receptors at standard test concentrations.
• Batch-to-batch consistency required: Use only high-purity (≥98%) lots to ensure reproducibility of results.

Workflow Integration & Parameters

Otilonium Bromide integrates into neuroscience and gastrointestinal workflows as follows:

• Preparation: Dissolve in DMSO, water, or ethanol at ≥28.18 mg/mL, 55.8 mg/mL, or 91 mg/mL, respectively; filter sterilize as needed.
• Storage: Store solid at -20°C; aliquot solutions for immediate use and discard unused portion after 24 hours at 4°C.
• Concentration range: Typical in vitro working concentrations are 0.1–10 μM; titrate for tissue type and species-specific responses.
• Controls: Include vehicle and positive controls to benchmark receptor specificity and functional readouts.

Adherence to these parameters ensures experimental reproducibility and minimizes confounding variables. The Otilonium Bromide B1607 kit from APExBIO is supplied with batch-specific documentation for traceability.

Conclusion & Outlook

Otilonium Bromide remains an essential tool for dissecting cholinergic signaling and modeling smooth muscle responses in preclinical research. Its high purity, robust solubility, and defined antimuscarinic action support its ongoing use in advanced neuroscience and gastrointestinal studies. Researchers should leverage its specificity and integrate best-practice handling to maximize data integrity. Future directions include expanded use in organoid and microphysiological systems, and the development of next-generation analogs for enhanced tissue targeting.